key: cord-0923744-zwpqwpry
authors: Luo, Pan; Liu, Yi; Qiu, Lin; Liu, Xiulan; Liu, Dong; Li, Juan
title: Tocilizumab treatment in COVID‐19: A single center experience
date: 2020-04-15
journal: J Med Virol
DOI: 10.1002/jmv.25801
sha: d47ad8502fec1a21a3bbf383ef5e508ab8fe02e2
doc_id: 923744
cord_uid: zwpqwpry

Tocilizumab (TCZ), a monoclonal antibody against interleukin‐6 (IL‐6), emerged as an alternative treatment for COVID‐19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID‐19 infected patients. The demographic, treatment, laboratory parameters of C‐reactive protein (CRP) and IL‐6 before and after TCZ therapy and clinical outcome in the 15 COVID‐19 patients were retrospectively assessed. Totally 15 patients with COVID‐19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL‐6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL‐6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID‐19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL‐6, the repeated dose of the TCZ is recommended.

in the 15 COVID-19 patients were retrospectively assessed. Totally 15 patients with COVID-19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL-6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL-6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL-6, the repeated dose of the TCZ is recommended. The first report of pathological characteristics of the patient who died from severe infection with SARS-CoV-2 showed that an increased concentration of highly proinflammatory cytokines. 1 Actually, the cytokine storms mediated by overproduction of proinflammatory cytokines have been observed in a large population of critically ill patients infected with COVID-19. 2, 3 Patients suffered from cytokine storms progress to cardiovascular collapse, multiple organ dysfunction, and death rapidly. Therefore, early identification, treatment, and prevention of the cytokine storms are of crucial importance for the patients.

IL-6 is a cytokine that plays an important role in inflammatory reaction and immune response. 4 The most recent clinical experiences in China suggested that IL-6 is one of the most important cytokines In this retrospective observational study, we aimed to present treatment responses of TCZ in the COVID-19 patients and to some extent, provide guidance for clinical use.

The patients infected with COVID-19, who were treated with TCZ from January 27 to 5 March 2020 at Zhongfaxincheng campus of Tongji Hospital in Wuhan, China, were recruited in this retrospective study. All patients were anonymous. The study was approved by the ethical committee of Huazhong University of Science and Technology.

The data of demographics, comorbidities, treatments, laboratory results, and clinical outcomes of the patients were obtained from the medical records. Based on Diagnosis and Treatment of Pneumonia Infected by Novel Coronavirus issued by the National Health Commission of China, the COVID-19 was classified into four types: mildly ill, moderately ill, seriously ill and critically ill. 5 The serum levels of CRP and IL-6 were observed before and after TCZ administration. CRP, an acute-phase reactant reflecting the inflammatory activity, was defined as elevated when it was higher than 5.0 mg/L. 2 The level of IL-6 was defined as elevated when it was higher than 7.0 pg/mL. 2 The patients whose laboratory data of CRP or IL-6 is complete deficiency before or after TCZ administration were considered as study dropouts. The most recent CRP or IL-6 values before TCZ administration was selected as the value of before TCZ therapy and the changes of the value after TCZ administration was observed for a week. The clinical outcome of the patients was evaluated within 1 week after TCZ therapy.

Statistical analysis was done with SPSS, version 23.0. Data are presented as median (min-max) or as the number and percentage, as appropriate. The Wilcoxon signed-rank test used to compare parameters whenever appropriate. A P-value of less than .05 was considered statistically significant.

Fifteen patients (12 males and 3 females) with COVID-19 were included in this study. The characteristics of patients, the use of TCZ and other anti-inflammatory drugs are summarized in Table 1 . The median age (min-max) of the patients was 73 (62-80) years. Two (13.3%) patients were moderately ill, six (40.0%) patients were seriously ill, and seven (46.7%) patients were critically ill. Ten (66.7%) patients had one or more co-morbidities, including cadiocerebrovascular diseases and endocrine system diseases. Eight (53.3%) patients received TCZ in combination with MP. Five (33.3%) patients received TCZ administration twice or more. The dose of TCZ used in patients was the range from 80 to 600 mg per time.

The laboratory findings of the 15 patients before, and in the first week after TCZ treatment are summarized in Table 2 . The CRP levels were far above the normal range in all patients before the start of TCZ therapy, and were rapidly ameliorated after the TCZ treatment.

The value of CRP at the first time it was detected after TCZ therapy was significantly decreased compared with before TCZ therapy, which dropped from 126.9 (10.7-257.9) to 11.2 (0.02-113.7) mg/L (P < .01). Although TCZ has benefits in relieving inflammatory activ- 

The present study suggested that a single dose of TCZ seems to fail to improve the disease activity in critically ill patients although it was used in combination with glucocorticoid. However, repeated doses (even repeated with a lower dose) of TCZ might improve the condition of critically ill patients. Therefore, in addition to the safety advantage, a repeated dose of TCZ is more likely to be effective than glucocorticoid in the treatment of COVID-19. Moreover, single dose of TCZ might be expected to benefit these seriously ill patients with about 10 times elevated IL-6. And the moderately ill patient with an extremely higher level of IL-6, almost 90 times of normal, could also benefit from repetitive TCZ therapy. Nevertheless, it seems that repeat the dose at a frequency of daily, every other day, or every 3 days with a totally two to three doses would be sensible in these critically ill patients or Our result should be evaluated with caution although we reported a good response in patients with TCZ. The number of cases reported is still small and using laboratory parameters to define the disease activity is still challenging. Furthermore, the treatment duration observed in our study may not be sufficient to make a final conclusion. Therefore, observation with a sufficient number of COVID-19 patients is still needed to document the effectiveness of TCZ.

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A panoramic review of IL-6: structure, pathophysiological roles and inhibitors

Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

IL-1 beta and IL-6 upregulation in children with H1N1 influenza virus infection

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Tocilizumab treatment in COVID-19: A single center experience

The authors declare that there are no conflict of interests.

JL and DL were responsible for the design of the study and revised the final manuscript. PL and YL contributed to the acquisition, analysis and interpretation of data. PL is responsible for summarizing all data and wrote the draft. All data were checked by LQ and XL.

http://orcid.org/0000-0002-5829-5142